Literature DB >> 12854039

Multiple sclerosis-like disease secondary to alpha interferon.

Toshihiko Matsuo1, Ryu Takabatake.   

Abstract

PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.
METHODS: Report of two cases. Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C. Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia. After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.
RESULTS: In both cases, magnetic resonance imaging demonstrated multiple small high-intensity areas in the cerebral white matter and spinal cord, while cerebrospinal fluid examination disclosed mononuclear cell increase and protein elevation including myelin basic protein, all of which simulated the features of multiple sclerosis. The two patients underwent several courses of pulse corticosteroid therapy, each course consisting of three days of methylprednisolone 1000 mg daily, resulting in visual recovery to some extent.
CONCLUSIONS: Optic neuritis in combination with other neurological signs, simulating multiple sclerosis, should be included in the list of adverse effects of recombinant and natural interferon alpha administration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12854039     DOI: 10.1076/ocii.10.4.299.15588

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  10 in total

1.  Multiple Sclerosis Like Condition in a Patient of Hepatitis C after Treatment with Interferon Alpha: A Case Report.

Authors:  Pyar Ali Fazil; Syed Mustafa Ali; Mustafa Zaboli; Syed Raza Shah
Journal:  J Clin Diagn Res       Date:  2015-05-01

2.  Side effects of interferon-alpha therapy.

Authors:  Stefan Sleijfer; Marjolein Bannink; Arthur R Van Gool; Wim H J Kruit; Gerrit Stoter
Journal:  Pharm World Sci       Date:  2005-12

Review 3.  Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping.

Authors:  Ippazio Cosimo Antonazzo; Emanuel Raschi; Luca Vignatelli; Elisa Baldin; Trond Riise; Roberto D'Alessandro; Fabrizio De Ponti; Elisabetta Poluzzi
Journal:  Drug Saf       Date:  2017-09       Impact factor: 5.606

Review 4.  Neurological complications of hepatitis C infection.

Authors:  Micheline McCarthy; Melissa R Ortega
Journal:  Curr Neurol Neurosci Rep       Date:  2012-12       Impact factor: 5.081

5.  Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon.

Authors:  Michael R Narkewicz; Philip Rosenthal; Kathleen B Schwarz; Arlene Drack; Todd Margolis; Michael X Repka
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-08       Impact factor: 2.839

Review 6.  Type I interferon in organ-targeted autoimmune and inflammatory diseases.

Authors:  Mary K Crow
Journal:  Arthritis Res Ther       Date:  2010-08-25       Impact factor: 5.156

7.  Lanreotide treatment in a patient with interferon-associated Graves' ophthalmopathy.

Authors:  Deng-Huang Su; Ying-Chun Chang; Shu-Lang Liao; Tien-Chun Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-09-28       Impact factor: 3.117

8.  Interferon-alpha2a and Vogt-Koyanagi-Harada disease: a double-edged sword?

Authors:  Valerie Touitou; Damien Sene; Christine Fardeau; Thi-Huong-Du Boutin; Pierre Duhaut; Jean-Charles Piette; Phuc LeHoang; Patrice Cacoub; Bahram Bodaghi
Journal:  Int Ophthalmol       Date:  2007-02-23       Impact factor: 2.029

9.  Bell's palsy during interferon alpha 2a treatment in a case with Behçet uveitis.

Authors:  Fatime Nilüfer Yalçindağ; Cem Alay
Journal:  F1000Res       Date:  2013-11-15

Review 10.  Side effects of cytokines approved for therapy.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2014-11       Impact factor: 5.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.